Market Place
Sourcing Support
Santhera Concludes Agreement with French Authorities on Raxone Reimbursement
08 Feb 2023 //
GLOBENEWSWIRE
Santhera Announces Positive Phase 4 LEROS Trial Data with Raxone
23 Jun 2021 //
GLOBENEWSWIRE
Chiesi`s Raxone recommended for use within NHS Wales
26 Apr 2021 //
PHARMATIMES
Santhera Completes Enrollment of Phase 3 SIDEROS Study with Puldysa®
20 May 2020 //
GLOBENEWSWIRE
EMA validates Santhera’s Puldysa MAA
27 Jun 2019 //
PHARMATIMES
Santhera submits MAA to EMA for Puldysa
28 May 2019 //
PHARMA TIMES
Chiesi pays $105m to license ophthalmological drug
28 May 2019 //
IN-PHA RMATECHNOLOGIST
Santhera, Chiesi Group Enter Raxone License Agreement
24 May 2019 //
CONTRACT PHARMA
Early access to Santhera’s DMD therapy Raxone extended in the UK
23 Jun 2018 //
PHARMA TIMES
Santhera’s Raxone fails in MS trial
06 Mar 2018 //
PHARMA TIMES
Santhera’s Raxone fails NIH’s MS study in latest setback, shares plunge
06 Mar 2018 //
ENDPTS
World first for Leeds as drug is prescribed
26 Feb 2018 //
YORKSHIRE EVENING POST
Santhera`s Raxone rejected in Europe for Duchenne muscular dystrophy
30 Jan 2018 //
PHARMAFILE
DMD patients in the UK win early access to Santhera’s Raxone
23 Jun 2017 //
PHARMA TIMES
Three new medicines cleared for use by NHS Scotland
09 May 2017 //
PHARMA TIMES
EU regulators review Santhera’s Raxone for Duchenne
22 Jun 2016 //
PHARMATIMES
New Review of Idebenone, Novel Therap Approach for Duchenne Muscular Dystrophy
11 Jan 2016 //
PR NEWS WIRE
Santhera Pharmaceuticals launches Raxone in Germany
01 Oct 2015 //
PBR
Santhera May Market Muscular Dystrophy Drug on its Own in U.S.
14 Apr 2015 //
BLOOMBERG
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.